FDA Warning Letter Calls Compounded GLP-1–Vitamin Mixes 'Pretextual' Copies
A September 2026 FDA warning letter to a large 503A pharmacy argues that adding B12 or niacinamide to semaglutide or tirzepatide does not, by itself, create a lawful patient-specific difference when done at scale.
By the GLP Semaglutide editorial team · Last updated October 11, 2026
On September 18, 2026, the FDA issued Warning Letter 738238 to Empower Clinic Services, LLC, doing business as Empower Pharmacy, following a November 2025 inspection of the firm's Houston 503A facility. According to the letter, investigators found that certain compounded tirzepatide/niacinamide and semaglutide/cyanocobalamin (vitamin B12) injections appeared to be essentially copies of FDA-approved semaglutide and tirzepatide products — and that production volume suggested the claimed differences were pretextual.
What the letter actually says
Under section 503A, a pharmacy generally may not compound regularly or in inordinate amounts drug products that are essentially copies of commercially available drugs, unless a change made for an identified individual patient produces a significant difference for that patient, as determined by the prescribing practitioner. The FDA named three combination products and said evidence included prescriptions lacking any significant-difference determination, determinations repeated verbatim across many records, and high monthly order volumes (specific counts were redacted in the published letter).
The agency also flagged third-party technology platforms that give prescribers pre-selected menu options for a significant-difference statement, saying that practice can undermine the individualized clinical judgment the statute requires.
How this fits prior FDA guidance
In an April 1, 2026 policy clarification, the FDA had already used a semaglutide-plus-vitamin-B12 combination as an illustrative example of a product that may still be treated as essentially a copy when the route matches and each active ingredient's strength is within 10% of a commercially available product. Legal analyses of the Empower letter describe it as applying that theory in an enforcement letter and explicitly using the word "pretextual" — language secondary coverage notes appears new in this GLP-1 compounding context.
Sterile-practice findings, separately
Beyond the essentially-a-copy analysis, the letter cited insanitary conditions and CGMP-related deficiencies for products intended to be sterile, including concerns about smoke studies under dynamic conditions, media fills, environmental monitoring, and quality-unit oversight. The FDA reviewed the firm's post-inspection responses and said some corrective actions could not be fully evaluated or appeared deficient based on the documentation provided.
What this means for readers
A warning letter is not a court judgment, and the recipient may dispute the agency's characterizations. It does state the FDA's current enforcement position that adding a vitamin such as B12 or niacinamide does not automatically create a lawful significant difference when the same co-formulation is produced at scale with templated documentation. Patients using compounded GLP-1 products should confirm with their clinician and pharmacy how any "significant difference" was documented for their specific case, and should not assume an added vitamin makes a compounded product equivalent to — or safer than — an FDA-approved pen.
Primary sources